Concepts (249)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 36 | 2023 | 20988 | 2.040 |
Why?
|
Radiation Oncology | 11 | 2023 | 563 | 1.820 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2022 | 801 | 1.450 |
Why?
|
Breast Implantation | 6 | 2022 | 219 | 1.190 |
Why?
|
Mammaplasty | 5 | 2022 | 1232 | 1.170 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 12 | 2022 | 1655 | 1.100 |
Why?
|
Breast Implants | 3 | 2022 | 407 | 0.890 |
Why?
|
Radiotherapy Dosage | 11 | 2022 | 2897 | 0.870 |
Why?
|
Radiotherapy, Conformal | 4 | 2022 | 548 | 0.870 |
Why?
|
Mastectomy | 11 | 2022 | 1817 | 0.800 |
Why?
|
Thoracic Wall | 3 | 2018 | 202 | 0.660 |
Why?
|
Breast Neoplasms, Male | 1 | 2021 | 212 | 0.650 |
Why?
|
Tattooing | 1 | 2019 | 57 | 0.630 |
Why?
|
Sarcopenia | 1 | 2023 | 370 | 0.610 |
Why?
|
Radiation Injuries | 3 | 2022 | 1189 | 0.610 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2018 | 123 | 0.570 |
Why?
|
Curriculum | 9 | 2022 | 3738 | 0.570 |
Why?
|
Medical Oncology | 4 | 2022 | 2317 | 0.530 |
Why?
|
Mastectomy, Segmental | 3 | 2021 | 955 | 0.530 |
Why?
|
Benchmarking | 1 | 2022 | 1045 | 0.520 |
Why?
|
Organs at Risk | 4 | 2022 | 359 | 0.510 |
Why?
|
Mediastinal Neoplasms | 1 | 2018 | 401 | 0.500 |
Why?
|
Breast | 4 | 2021 | 1963 | 0.460 |
Why?
|
Women's Health | 1 | 2022 | 2065 | 0.410 |
Why?
|
Protons | 4 | 2022 | 1112 | 0.410 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2013 | 136 | 0.400 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1323 | 0.400 |
Why?
|
Neoplasms, Second Primary | 1 | 2020 | 1051 | 0.400 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 159 | 0.400 |
Why?
|
Heart | 3 | 2022 | 4403 | 0.390 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2022 | 2118 | 0.380 |
Why?
|
Radiobiology | 2 | 2020 | 90 | 0.330 |
Why?
|
Lymphoma | 1 | 2018 | 1899 | 0.310 |
Why?
|
Internship and Residency | 4 | 2023 | 5878 | 0.310 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2023 | 3514 | 0.310 |
Why?
|
Cerebellar Neoplasms | 1 | 2013 | 586 | 0.300 |
Why?
|
Medulloblastoma | 1 | 2013 | 677 | 0.300 |
Why?
|
Lymph Nodes | 1 | 2019 | 3461 | 0.300 |
Why?
|
Photons | 4 | 2019 | 589 | 0.290 |
Why?
|
Female | 44 | 2023 | 392148 | 0.280 |
Why?
|
Humans | 65 | 2023 | 760617 | 0.270 |
Why?
|
Neoplasms | 6 | 2023 | 22131 | 0.240 |
Why?
|
Clinical Clerkship | 3 | 2015 | 564 | 0.230 |
Why?
|
Cultural Diversity | 2 | 2023 | 369 | 0.220 |
Why?
|
Patient Participation | 1 | 2013 | 1443 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9277 | 0.220 |
Why?
|
Hypertension | 1 | 2022 | 8529 | 0.200 |
Why?
|
Seroma | 1 | 2022 | 73 | 0.200 |
Why?
|
Program Evaluation | 4 | 2020 | 2486 | 0.200 |
Why?
|
Family Leave | 1 | 2021 | 18 | 0.190 |
Why?
|
Supreme Court Decisions | 1 | 2022 | 133 | 0.180 |
Why?
|
Education, Nursing | 1 | 2021 | 80 | 0.180 |
Why?
|
Relative Biological Effectiveness | 2 | 2021 | 311 | 0.180 |
Why?
|
Sick Leave | 1 | 2021 | 105 | 0.180 |
Why?
|
Clinical Trials as Topic | 3 | 2023 | 7995 | 0.170 |
Why?
|
Cranial Irradiation | 2 | 2013 | 390 | 0.170 |
Why?
|
Accreditation | 1 | 2023 | 473 | 0.170 |
Why?
|
Students, Medical | 4 | 2021 | 1934 | 0.170 |
Why?
|
Thorax | 1 | 2022 | 555 | 0.160 |
Why?
|
Physics | 1 | 2019 | 91 | 0.160 |
Why?
|
Troponin | 1 | 2022 | 502 | 0.160 |
Why?
|
Retrospective Studies | 13 | 2023 | 80566 | 0.160 |
Why?
|
Rib Fractures | 1 | 2020 | 128 | 0.160 |
Why?
|
Education, Medical, Graduate | 2 | 2023 | 2371 | 0.150 |
Why?
|
Craniopharyngioma | 1 | 2021 | 276 | 0.150 |
Why?
|
Canada | 2 | 2022 | 2118 | 0.150 |
Why?
|
Necrosis | 1 | 2022 | 1610 | 0.150 |
Why?
|
Nausea | 1 | 2021 | 679 | 0.150 |
Why?
|
Lymphatic Metastasis | 2 | 2018 | 2913 | 0.150 |
Why?
|
Safety | 1 | 2022 | 1149 | 0.150 |
Why?
|
Vomiting | 1 | 2021 | 651 | 0.140 |
Why?
|
Moyamoya Disease | 1 | 2021 | 265 | 0.140 |
Why?
|
Hematoma | 1 | 2022 | 762 | 0.140 |
Why?
|
Policy | 1 | 2021 | 506 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2019 | 349 | 0.140 |
Why?
|
Radiation Tolerance | 1 | 2019 | 478 | 0.130 |
Why?
|
Patient Care Planning | 1 | 2021 | 905 | 0.130 |
Why?
|
Physician-Patient Relations | 3 | 2021 | 3239 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2020 | 802 | 0.130 |
Why?
|
Treatment Outcome | 11 | 2023 | 64568 | 0.130 |
Why?
|
Patient Positioning | 1 | 2018 | 326 | 0.120 |
Why?
|
Aged | 14 | 2023 | 169042 | 0.120 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2023 | 1520 | 0.120 |
Why?
|
Tumor Burden | 1 | 2021 | 1892 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 587 | 0.120 |
Why?
|
Cisplatin | 1 | 2021 | 1650 | 0.120 |
Why?
|
Postoperative Care | 2 | 2018 | 1467 | 0.120 |
Why?
|
Postoperative Complications | 3 | 2022 | 15612 | 0.110 |
Why?
|
Pulmonary Fibrosis | 1 | 2018 | 505 | 0.110 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6807 | 0.110 |
Why?
|
Fatigue | 1 | 2021 | 1550 | 0.110 |
Why?
|
Vision Disorders | 1 | 2021 | 1088 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 733 | 0.110 |
Why?
|
Middle Aged | 18 | 2023 | 220584 | 0.110 |
Why?
|
Headache | 1 | 2021 | 1255 | 0.100 |
Why?
|
Quality of Life | 5 | 2022 | 13347 | 0.100 |
Why?
|
Propensity Score | 1 | 2020 | 1911 | 0.100 |
Why?
|
Health Services Needs and Demand | 1 | 2020 | 1400 | 0.100 |
Why?
|
Ventricular Function, Left | 2 | 2022 | 3873 | 0.100 |
Why?
|
Needs Assessment | 1 | 2018 | 1139 | 0.100 |
Why?
|
Acculturation | 1 | 2013 | 178 | 0.100 |
Why?
|
Surgical Flaps | 1 | 2020 | 1670 | 0.090 |
Why?
|
Terminal Care | 2 | 2013 | 1755 | 0.090 |
Why?
|
Schizophrenia, Paranoid | 1 | 2011 | 103 | 0.090 |
Why?
|
Stroke Volume | 2 | 2022 | 5486 | 0.090 |
Why?
|
Adult | 16 | 2023 | 220969 | 0.090 |
Why?
|
Endocrine System Diseases | 1 | 2013 | 249 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1745 | 0.090 |
Why?
|
Terminally Ill | 1 | 2013 | 240 | 0.090 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2020 | 1080 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2021 | 2768 | 0.090 |
Why?
|
Attitude to Death | 1 | 2013 | 400 | 0.090 |
Why?
|
Bone Density Conservation Agents | 1 | 2017 | 794 | 0.090 |
Why?
|
Peptide Fragments | 1 | 2022 | 5110 | 0.080 |
Why?
|
Echocardiography | 1 | 2022 | 4987 | 0.080 |
Why?
|
Massachusetts | 2 | 2021 | 8833 | 0.080 |
Why?
|
Pectoralis Muscles | 2 | 2020 | 84 | 0.080 |
Why?
|
Feedback | 3 | 2021 | 790 | 0.080 |
Why?
|
Prospective Studies | 6 | 2022 | 54360 | 0.080 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2020 | 1784 | 0.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 11736 | 0.080 |
Why?
|
United States | 7 | 2022 | 72272 | 0.080 |
Why?
|
Interviews as Topic | 2 | 2013 | 2697 | 0.080 |
Why?
|
Patient Preference | 2 | 2013 | 925 | 0.080 |
Why?
|
Young Adult | 5 | 2023 | 59179 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 5239 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2553 | 0.070 |
Why?
|
Career Choice | 1 | 2014 | 756 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6474 | 0.070 |
Why?
|
Radiology | 1 | 2021 | 2113 | 0.070 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2013 | 781 | 0.070 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39063 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5822 | 0.070 |
Why?
|
Body Height | 1 | 2013 | 1565 | 0.070 |
Why?
|
Hospice Care | 1 | 2013 | 677 | 0.070 |
Why?
|
Education, Medical, Undergraduate | 1 | 2015 | 1068 | 0.070 |
Why?
|
Cultural Competency | 1 | 2009 | 299 | 0.070 |
Why?
|
Survival Rate | 2 | 2018 | 12719 | 0.070 |
Why?
|
Infant | 2 | 2021 | 36152 | 0.060 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2527 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2023 | 26049 | 0.060 |
Why?
|
Radiosurgery | 1 | 2014 | 1339 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2021 | 11116 | 0.060 |
Why?
|
Child, Preschool | 2 | 2021 | 42188 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5424 | 0.060 |
Why?
|
Male | 11 | 2023 | 360358 | 0.060 |
Why?
|
Neoadjuvant Therapy | 3 | 2020 | 2827 | 0.050 |
Why?
|
Cause of Death | 1 | 2013 | 3683 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3088 | 0.050 |
Why?
|
Lung | 2 | 2018 | 9998 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3209 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2014 | 9026 | 0.050 |
Why?
|
Aged, 80 and over | 4 | 2023 | 58894 | 0.050 |
Why?
|
Consensus | 2 | 2021 | 3117 | 0.040 |
Why?
|
Linear Energy Transfer | 1 | 2021 | 151 | 0.040 |
Why?
|
Governing Board | 1 | 2019 | 50 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2021 | 883 | 0.040 |
Why?
|
Program Development | 2 | 2015 | 1293 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2019 | 183 | 0.040 |
Why?
|
Logistic Models | 1 | 2013 | 13245 | 0.040 |
Why?
|
Pandemics | 3 | 2022 | 8645 | 0.040 |
Why?
|
Surgical Mesh | 1 | 2020 | 311 | 0.030 |
Why?
|
Radiology, Interventional | 1 | 2021 | 476 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2022 | 1663 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2013 | 14591 | 0.030 |
Why?
|
Cost Allocation | 1 | 2016 | 49 | 0.030 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2019 | 717 | 0.030 |
Why?
|
Lung Neoplasms | 2 | 2019 | 13382 | 0.030 |
Why?
|
Certification | 1 | 2019 | 418 | 0.030 |
Why?
|
Single-Blind Method | 1 | 2020 | 1575 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2021 | 5491 | 0.030 |
Why?
|
Educational Measurement | 2 | 2015 | 1252 | 0.030 |
Why?
|
Fluorouracil | 1 | 2020 | 1642 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 529 | 0.030 |
Why?
|
Models, Econometric | 1 | 2016 | 215 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 651 | 0.030 |
Why?
|
Organ Specificity | 1 | 2020 | 1964 | 0.030 |
Why?
|
Device Removal | 1 | 2020 | 629 | 0.030 |
Why?
|
Prognosis | 3 | 2023 | 29600 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2020 | 1257 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 612 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 857 | 0.030 |
Why?
|
Chicago | 1 | 2014 | 254 | 0.030 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 926 | 0.030 |
Why?
|
Pyrazines | 1 | 2019 | 1202 | 0.030 |
Why?
|
Diphosphonates | 1 | 2017 | 635 | 0.030 |
Why?
|
Child | 1 | 2021 | 80079 | 0.030 |
Why?
|
Adolescent | 1 | 2021 | 88234 | 0.030 |
Why?
|
Markov Chains | 1 | 2016 | 965 | 0.030 |
Why?
|
Advance Directives | 1 | 2013 | 249 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 10199 | 0.020 |
Why?
|
Imidazoles | 1 | 2017 | 1175 | 0.020 |
Why?
|
Fear | 1 | 2020 | 1477 | 0.020 |
Why?
|
Catheterization | 1 | 2016 | 1428 | 0.020 |
Why?
|
Clinical Competence | 2 | 2018 | 4789 | 0.020 |
Why?
|
Social Support | 1 | 2020 | 2174 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 3 | 2018 | 20556 | 0.020 |
Why?
|
Age Factors | 2 | 2017 | 18381 | 0.020 |
Why?
|
Retreatment | 1 | 2011 | 596 | 0.020 |
Why?
|
Reoperation | 1 | 2020 | 4300 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2506 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 1722 | 0.020 |
Why?
|
Life Expectancy | 1 | 2016 | 1239 | 0.020 |
Why?
|
Delusions | 1 | 2011 | 298 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8516 | 0.020 |
Why?
|
Hospitals, Teaching | 1 | 2014 | 1155 | 0.020 |
Why?
|
Cell Survival | 1 | 2019 | 5780 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2023 | 12447 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4237 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3849 | 0.020 |
Why?
|
Radiometry | 1 | 2013 | 812 | 0.020 |
Why?
|
Societies, Medical | 1 | 2019 | 3900 | 0.020 |
Why?
|
Biopsy | 1 | 2019 | 6762 | 0.020 |
Why?
|
Hospitals, General | 1 | 2011 | 798 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2020 | 12043 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2016 | 1167 | 0.020 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2011 | 423 | 0.020 |
Why?
|
Animals | 1 | 2018 | 168201 | 0.020 |
Why?
|
Faculty | 1 | 2009 | 383 | 0.020 |
Why?
|
Steroids | 1 | 2011 | 929 | 0.020 |
Why?
|
Problem-Based Learning | 1 | 2009 | 356 | 0.020 |
Why?
|
Internet | 1 | 2018 | 3090 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2013 | 2423 | 0.020 |
Why?
|
Risk Factors | 3 | 2020 | 74115 | 0.020 |
Why?
|
Remission Induction | 1 | 2011 | 2391 | 0.020 |
Why?
|
Recurrence | 1 | 2017 | 8426 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2015 | 2756 | 0.020 |
Why?
|
Heart Ventricles | 1 | 2017 | 3796 | 0.020 |
Why?
|
Survival Analysis | 1 | 2017 | 10073 | 0.010 |
Why?
|
HIV Infections | 1 | 2011 | 17337 | 0.010 |
Why?
|
Pilot Projects | 1 | 2018 | 8618 | 0.010 |
Why?
|
Dexamethasone | 1 | 2011 | 1947 | 0.010 |
Why?
|
Mutation | 2 | 2019 | 30016 | 0.010 |
Why?
|
Time Factors | 2 | 2018 | 39913 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10432 | 0.010 |
Why?
|
Adaptation, Psychological | 1 | 2013 | 2629 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 16967 | 0.010 |
Why?
|
Coronary Disease | 1 | 2016 | 5912 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8207 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9313 | 0.010 |
Why?
|
Caregivers | 1 | 2013 | 2241 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2016 | 14648 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 6961 | 0.010 |
Why?
|
Palliative Care | 1 | 2011 | 3592 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20074 | 0.010 |
Why?
|
Disease Progression | 1 | 2011 | 13495 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5319 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2011 | 6925 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 36402 | 0.000 |
Why?
|
Concepts
(249)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(97)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_